Myelosuppression var almindeligvis reversibel og kunne oftest håndteres ved midlertidigt at afbryde dasatinib eller ved dosisreduktion (se pkt.
23 reversible and usually managed by withholding dasatinib temporarily or by dose reduction (see sections 4.2 and 4.8).